GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncodesign Precision Medicine SA (XPAR:ALOPM) » Definitions » Current Deferred Revenue

Oncodesign Precision Medicine (XPAR:ALOPM) Current Deferred Revenue : €0.00 Mil (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Oncodesign Precision Medicine Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Oncodesign Precision Medicine's current deferred revenue for the quarter that ended in Dec. 2024 was €0.00 Mil.

Oncodesign Precision Medicine Current Deferred Revenue Historical Data

The historical data trend for Oncodesign Precision Medicine's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncodesign Precision Medicine Current Deferred Revenue Chart

Oncodesign Precision Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Current Deferred Revenue
- - - - -

Oncodesign Precision Medicine Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Current Deferred Revenue Get a 7-Day Free Trial - - - - -

Oncodesign Precision Medicine Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Oncodesign Precision Medicine's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncodesign Precision Medicine Business Description

Traded in Other Exchanges
Address
18 rue Jean Mazen, Dijon, FRA, 21000
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.

Oncodesign Precision Medicine Headlines

No Headlines